Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
Conference call details are as follows:
A recording of the call will be available for telephone replay until May 21, 2010.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.
-- Live conference call (US): (888) 889-1309 -- Live conference call (Outside the US): (773) 756-0161 -- Passcode: BIOTECH
SOURCE Regeneron Pharmaceuticals, Inc.
You May Also Like